The Nuts & Bolts of PBM

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

Retrieved on:

Wednesday, May 18, 2022

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of the federal securities laws.

Key Points:

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of the federal securities laws.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance.
Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

Retrieved on:

Wednesday, May 18, 2022

Legal, Professional Services, News, GoodRx, NASDAQ, Telephone, Company, The Nuts & Bolts of PBM, Suite, Letter, Renewable energy

Law Offices of Howard G. Smith continues its investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of federal securities laws.

Key Points:

Law Offices of Howard G. Smith continues its investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of federal securities laws.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance.
As a result, GoodRx believe[s] it is unlikely [it] will be able to achieve the FY 2022 guidance previously provided.
On this news, GoodRxs stock fell $2.78, or 25.9%, to close at $7.97 on May 10, 2022, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Clariant, TG Therapeutics, Coinbase, and GoodRx and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, May 17, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points:

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
On this news, shares of Clariant AG ADR shares fell more than 14% in intraday trading on February 14, 2022.
On this news, TG Therapeutics' stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
For more information on the TG Therapeutics investigation go to: https://bespc.com/cases/TGTX
On May 10, 2022, Coinbase reported its first quarter 2022 results.

GOODRX ALERT: Bragar Eagel & Squire, P.C. Is Investigating GoodRx, Inc. on Behalf of GoodRx Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Friday, May 13, 2022

Legal, Professional Services, News, P.C, GoodRx, NASDAQ, Telephone, Company, The Nuts & Bolts of PBM, Jeanne Eagels (film), Letter, Renewable energy

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX) on behalf of GoodRx stockholders.

Key Points:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX) on behalf of GoodRx stockholders.
Our investigation concerns whether GoodRx has violated the federal securities laws and/or engaged in other unlawful business practices.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance.
As a result, GoodRx believe[s] it is unlikely [it] will be able to achieve the FY 2022 guidance previously provided.

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

Retrieved on:

Thursday, May 12, 2022

Legal, Professional Services, News, GoodRx, NASDAQ, LLP, Company, Plasma protein binding, Kirby, Letter, The Nuts & Bolts of PBM, Private investigator, Renewable energy

The law firm of Kirby McInerney LLP is investigating potential claims against GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ).

Key Points:

The law firm of Kirby McInerney LLP is investigating potential claims against GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ).
The investigation concerns whether GoodRx has violated the federal securities laws and/or engaged in other unlawful business practices.
On February 28, 2022, after the market closed, GoodRx announced disappointing fourth quarter 2021 and full-year earnings results and offered poor guidance for 2022.
Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

Retrieved on:

Wednesday, May 11, 2022

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of the federal securities laws.

Key Points:

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of the federal securities laws.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance.
Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

Retrieved on:

Wednesday, May 11, 2022

Legal, Professional Services, News, GoodRx, NASDAQ, Telephone, Company, The Nuts & Bolts of PBM, Suite, Letter, Renewable energy

Law Offices of Howard G. Smith announces an investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of federal securities laws.

Key Points:

Law Offices of Howard G. Smith announces an investigation on behalf of GoodRx Holdings, Inc. (GoodRx or the Company) (NASDAQ: GDRX ) investors concerning the Companys possible violations of federal securities laws.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance.
As a result, GoodRx believe[s] it is unlikely [it] will be able to achieve the FY 2022 guidance previously provided.
On this news, GoodRxs stock fell $2.78, or 25.9%, to close at $7.97 on May 10, 2022, thereby injuring investors.

GoodRx Appoints Raj Beri as Chief Operating Officer, Mark Hull as Chief Product Officer and Vina Leite as Chief People Officer

Retrieved on:

Monday, May 9, 2022

With more than 20 years in the business operations space, Raj will lead continued growth and expansion at GoodRx, while helping increase value across the prescriptions business.

Key Points:

With more than 20 years in the business operations space, Raj will lead continued growth and expansion at GoodRx, while helping increase value across the prescriptions business.
In addition, Mark Hull has been named the first ever Chief Product Officer to help the company build industry-leading solutions for consumers, providers and pharmacists.
Vina Leite has joined GoodRx as the companys first Chief People Officer.
Raj, Mark, Vina and Scott are innovative, forward-thinking executives who believe in GoodRxs vision and core values.

Xevant Ranks No. 42 on Inc. Magazine's List of the Rocky Mountain Region's Fastest-Growing Private Companies

Retrieved on:

Thursday, March 24, 2022

Globe One Digital, Oxford Health Plans, LinkedIn, Growth, TPA, Broker, Financial Times and McKinsey Business Book of the Year Award, Data analysis, CEO, The Nuts & Bolts of PBM, Name, Great Places, Industry, Database, GLOBE, Rocky Mountains, Oil, LEHI

42 on its third annual Inc. 5000 Regionals Rocky Mountain list, the most prestigious ranking of the fastest-growing private companies based in Colorado, Idaho, Montana, Nevada, Utah, and Wyoming.

Key Points:

42 on its third annual Inc. 5000 Regionals Rocky Mountain list, the most prestigious ranking of the fastest-growing private companies based in Colorado, Idaho, Montana, Nevada, Utah, and Wyoming.
Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Rocky Mountain region economy's most dynamic segmentits independent small businesses.
"It's an honor for Xevant to rank among the fastest-growing companies in our region.
The companies on this list show a remarkable rate of growth across all industries in the Rocky Mountain region.

First-Of-Its-Kind Oncology State Legislation Tracking Tool

Retrieved on:

Tuesday, March 15, 2022

CAZENOVIA, N.Y., March 15, 2022 /PRNewswire/ -- Today, NCODA announces the launch of its new and unique, comprehensive Oncology State Legislation Tracking Tool. This new NCODA member resource is the first-of-its-kind within the oncology space that allows healthcare professionals and other users to stay up-to-date on the latest in state legislation pertaining to issues such as PBMs and copay accumulators. Unlike other state legislation trackers, this tool encompasses all updates throughout the United States in one location, and is updated on a weekly basis.

Key Points:

CAZENOVIA, N.Y., March 15, 2022 /PRNewswire/ --Today, NCODA announces the launch of its new and unique, comprehensive Oncology State Legislation Tracking Tool .
The NCODA Oncology State Legislation Tracking Tool will include relevant bill numbers, complete bill readings, as well as a brief summary and a 'why it matters' section for each bill.
In addition to the many member resources that NCODA offers, the Oncology State Legislation Tracking Tool is a valuable way for the oncology community to be informed on recent state legislative issues.
To access the Oncology State Legislation Tracking Tool , users must be an NCODA Member.